Case Study

Rho's Approach To Overcoming Enrollment Challenges In A CNS Trial

Source: Rho

By Nancy Yovetich, Ph.D., Principal Research Scientist

Hand holding magnifier glass hiring recruit

A mid-sized biotech company running a randomized, doubleblind, placebo controlled (1:1) Phase 3 CNS pain study, with a single treatment administration, had achieved ex-US approval yet faced significant enrollment challenges when a modified version of the study was implemented in the US. With a goal of 300 participants, the rate of enrollment sat at a mere 0.5 subjects a month. The best laid plans weren’t cutting it.

The Problem: Enrollment Challenges

Initial efforts to strategically adjust the enrollment criterion were disappointingly ineffective. Patient enrollment rates were lagging far behind goals, threatening to delay program start-up and obstruct research advancement. They turned to our experts for critical, creative thinking and innovative solutions.

The Solution

Implement a series of enrollment strategies and innovative solutions that allow for the opening of additional recruitment pathways to encourage greater participation, while reducing sites’ operational burden and maintaining the integrity of the trial.

VIEW THE CASE STUDY!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: